A pilot, single-arm, open-label, 12-week (with a two-week follow-up) multicenter, Non-IND, IRB-Approved Clinical Study to assess the safety, tolerability and physiological impact of AXA1125 on the normal liver structures and functions in subjects with type 2 diabetes and non-alcoholic fatty liver disease
Latest Information Update: 23 Mar 2020
At a glance
- Drugs AXA 1125 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions
- 23 Mar 2020 New trial record
- 03 Mar 2020 Results published in the Axcella Health SEC filing.